GlaxoSmithKline is edging higher amid renewed speculation it could be interested in US group BioMarin. BioMarin, which specialises in rare diseases, saw its shares climb more than 2% on Thursday to $42.39. There has been much talk in recent weeks that the company was a target for a larger pharmaceutical group, and some traders believe news could come soon. A price of up to $65 a share has been mentioned, which would value Biomarin at more than $7bn. Glaxo is currently up 11p at 1446.5p after submitting a new lung disease treatment for US and European approval.
